{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Orlando&page=41&state=Florida", "query": { "state": "Florida", "city": "Orlando", "page": 41 }, "page_size": 10 }, "pagination": { "page": 41, "page_size": 10, "total_count": 6848, "total_pages": 685, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Orlando&page=42&state=Florida&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Orlando&page=40&state=Florida&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-02T21:31:43.677Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02943564", "title": "A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Depressive Disorder, Major" ], "interventions": [ { "name": "Rapastinel", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Naurex, Inc, an affiliate of Allergan plc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 658, "start_date": "2016-11-01", "completion_date": "2018-12-18", "has_results": true, "last_update_posted_date": "2019-12-27", "last_synced_at": "2026-11-02T21:31:43.677Z", "location_count": 66, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 56 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02943564" }, { "nct_id": "NCT04389632", "title": "A Study of Sigvotatug Vedotin in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Non-Small Cell Lung", "Squamous Cell Carcinoma of Head and Neck", "HER2 Negative Breast Neoplasms", "Esophageal Squamous Cell Carcinoma", "Esophageal Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Ovarian Neoplasms", "Cutaneous Squamous Cell Cancer", "Exocrine Pancreatic Adenocarcinoma", "Urinary Bladder Neoplasms", "Uterine Cervical Neoplasms", "Stomach Neoplasms" ], "interventions": [ { "name": "sigvotatug vedotin", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1006, "start_date": "2020-06-08", "completion_date": "2029-03-22", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-11-02T21:31:43.677Z", "location_count": 106, "location_summary": "Anchorage, Alaska • Fayetteville, Arkansas • Rogers, Arkansas + 61 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04389632" }, { "nct_id": "NCT03520998", "title": "A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alzheimer Disease", "Mild to Moderate Alzheimer Disease" ], "interventions": [ { "name": "GRF6019", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alkahest, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "60 Years to 90 Years" }, "enrollment_count": 47, "start_date": "2018-04-16", "completion_date": "2019-05-24", "has_results": true, "last_update_posted_date": "2021-01-29", "last_synced_at": "2026-11-02T21:31:43.677Z", "location_count": 10, "location_summary": "Lemon Grove, California • Long Beach, California • San Diego, California + 7 more", "locations": [ { "city": "Lemon Grove", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Hallandale", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03520998" }, { "nct_id": "NCT06285916", "title": "A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Depression, Postpartum", "Postpartum Depression", "Post-partum Depression", "Postnatal Depression", "Post-Natal Depression" ], "interventions": [ { "name": "NORA520 Dose 1", "type": "DRUG" }, { "name": "NORA520 Dose 2", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TWi Biotechnology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 93, "start_date": "2024-03-28", "completion_date": "2025-10-06", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-11-02T21:31:43.677Z", "location_count": 18, "location_summary": "Bentonville, Arkansas • Anaheim, California • Canoga Park, California + 15 more", "locations": [ { "city": "Bentonville", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Canoga Park", "state": "California" }, { "city": "Sherman Oaks", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06285916" }, { "nct_id": "NCT05687916", "title": "A Study of TAK-861 in Participants With Narcolepsy Type 2", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Narcolepsy Type 2" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "TAK-861 2 mg", "type": "DRUG" }, { "name": "TAK-861 2 mg and 5 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "16 Years to 70 Years" }, "enrollment_count": 71, "start_date": "2023-01-09", "completion_date": "2023-12-25", "has_results": true, "last_update_posted_date": "2025-01-09", "last_synced_at": "2026-11-02T21:31:43.677Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Redwood City, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Redwood City", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05687916" }, { "nct_id": "NCT00623428", "title": "A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 235, "start_date": "2008-06", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2013-07-22", "last_synced_at": "2026-11-02T21:31:43.677Z", "location_count": 38, "location_summary": "Birmingham, Alabama • La Jolla, California • Lancaster, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00623428" }, { "nct_id": "NCT00788528", "title": "Open-Label Extension (OLE) Study for Safety and Efficacy of Velneperit (S-2367) in Obese Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Obesity" ], "interventions": [ { "name": "S-2367 (velneperit)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shionogi", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 766, "start_date": "2008-08", "completion_date": "2010-03", "has_results": false, "last_update_posted_date": "2018-05-01", "last_synced_at": "2026-11-02T21:31:43.677Z", "location_count": 73, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 67 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00788528" }, { "nct_id": "NCT00645021", "title": "Study Examining The Effect Of Hepatic Impairment On Safety, Toleration And How The Body Processes An Experimental Drug", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Obesity", "Hepatic Insufficiency" ], "interventions": [ { "name": "CP-945,598", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 24, "start_date": "2008-04", "completion_date": "2008-10", "has_results": false, "last_update_posted_date": "2009-08-27", "last_synced_at": "2026-11-02T21:31:43.677Z", "location_count": 2, "location_summary": "Miami, Florida • Orlando, Florida", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00645021" }, { "nct_id": "NCT05822752", "title": "Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Budigalimab", "type": "DRUG" }, { "name": "Livmoniplimab", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2023-09-21", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2025-08-14", "last_synced_at": "2026-11-02T21:31:43.677Z", "location_count": 20, "location_summary": "Prescott Valley, Arizona • Springdale, Arkansas • Los Angeles, California + 15 more", "locations": [ { "city": "Prescott Valley", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05822752" }, { "nct_id": "NCT03150693", "title": "Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "B Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Allopurinol", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Pegylated L-Asparaginase", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Thioguanine", "type": "DRUG" }, { "name": "Inotuzumab Ozogamicin", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "18 Years to 39 Years" }, "enrollment_count": 303, "start_date": "2017-09-20", "completion_date": "2028-04-01", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-11-02T21:31:43.677Z", "location_count": 455, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 279 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03150693" } ] }